Day: March 29, 2022

PALO ALTO, Calif. and SUZHOU, China, March 29, 2022 (GLOBE NEWSWIRE) — Gracell Biotechnologies Inc. (NASDAQ: GRCL) (“Gracell”), a global clinical-stage biopharmaceutical company dedicated to discovering and developing highly efficacious and affordable cell therapies for the treatment of cancer, today announced that the management team will participate in and attend one-on-one meetings at three investor conferences in April 2022 as follows: Wells Fargo Biotech ForumOne-on-one meetings: April 12 – 13Location: Palm Beach Gardens, Florida 21st Annual Needham Virtual Healthcare ConferenceOne-on-one meetings: April 14Presentation: April 14, 2022, 9:30 am ET Webcast link: https://ir.gracellbio.com/news-events/events-and-presentations The replay of the presentation can be accessed through the “News and Events” section of Gracell’s...

Company Begins Providing Services in Thirteenth State DENVER, March 29, 2022 (GLOBE NEWSWIRE) — Assure Holdings Corp. (the “Company” or “Assure”) (NASDAQ: IONM), a provider of intraoperative neuromonitoring (“IONM”) and remote neurology services, is pleased to announce that it has performed its first neuromonitoring case in the Twin Cities area of Minnesota. “Assure is continuing to generate strong organic growth and is pleased to expand the Company’s operational footprint into our thirteenth state. Minnesota holds considerable growth potential, and we are pleased to engage in this market with a distinguished physician in the state,” said John A. Farlinger, Assure’s executive chairman and CEO. “This opportunity developed as a result of a relationship we have fostered with a medical device distributor, highlighting the traction...

New vulnerability assessment capabilities deliver necessary cloud workload context to enhance cloud-native security platform BOSTON, March 29, 2022 (GLOBE NEWSWIRE) — Rapid7, Inc. (NASDAQ: RPD), a leading provider of security visibility, analytics and automation, today announced new cloud workload protection capabilities for InsightCloudSec, the company’s fully-integrated cloud-native security platform (CNSP). These enhancements, which include native vulnerability assessment for container and Kubernetes environments, leverage Rapid7’s proven, industry-leading vulnerability assessment technology delivered via an agentless experience that is purpose built for cloud-native environments. As organizations increasingly move to public cloud infrastructure-as-a-service (IaaS) to fuel new initiatives or replace on-premises systems, the...

Top-line results from GULLIVER-2 trial on track for the fourth quarter of 2022 Part 1 of GULLIVER-2 trial completed with positive results as previously announced in December 2021 BOSTON, March 29, 2022 (GLOBE NEWSWIRE) — Galecto, Inc. (NASDAQ: GLTO), a clinical-stage biotechnology company focused on the development of novel treatments for fibrosis and cancer, today announced it has completed enrollment in Parts 2 and 3 of its ongoing 3-part Phase 1b/2a trial of GB1211, GULLIVER-2, in liver cirrhosis. GB1211 is a selective, oral small molecule inhibitor of galectin-3 being studied in liver cirrhosis, a severe, progressive disease that ultimately leads to liver failure, and for which there are limited treatment options. GULLIVER-2 is an innovative hybrid trial, combining a hepatic impairment trial of safety, tolerability and pharmacokinetics...

– Phase 3 ASSERT study on track to report topline data by the end of year – Albireo launches Expanded Access Program (EAP) for Alagille syndrome patients BOSTON, March 29, 2022 (GLOBE NEWSWIRE) — Albireo Pharma, Inc. (Nasdaq: ALBO), a rare liver disease company developing novel bile acid modulators, today announced the completion of patient enrollment in the ASSERT study, a Phase 3 pivotal trial of Bylvay (odevixibat) in patients with Alagille syndrome (ALGS). Topline results are expected to be available by the end of the year, consistent with guidance, and with the enrollment of 52 patients versus an original target of 45. ASSERT is a gold standard, global, double-blind, randomized, placebo-controlled trial designed to evaluate the safety and efficacy of Bylvay in patients with ALGS over 24 weeks. Both the U.S. FDA and EMA have...

Vancouver, BC, March 29, 2022 (GLOBE NEWSWIRE) — Skyharbour Resources Ltd.’s (TSX-V:SYH) (OTCQB:SYHBF) (Frankfurt:SC1P) (the “Company”) partner company Azincourt Energy (“Azincourt), is pleased to announce that the 2022 exploration program has been completed at the East Preston uranium project, located in the western Athabasca Basin, Saskatchewan, Canada. Drilling for the 2022 winter season at the East Preston Project commenced in late January and a total of 5,004 metres were completed in 19 drill holes, which was cut slightly short due to the onset of warm weather. Drilling was focused on the G-, K-, and H-Zones with prior progress reported in news releases dated February 14th, 2022, March 1st, 2022, and March 16th, 2022. Packing up and demobilizing of the drill equipment and camp is underway with decommissioning of the road expected...

SFLMaven Scores Another Strong Week of Sales with Nearly $285k for the Seven Days Ended March 24 Heavy Platinum 6.25CTW VS1/F diamond cluster floral ribbon brooch. Sold for $4,739 at last week’s SFLMaven Famous Thursday Night AuctionSFLMaven Scores Another Strong Week of Sales with Nearly $285k for the Seven Days Ended March 24 Heavy 14k yellow gold 10.29ct diamond line tennis bracelet. Sold for $5,600FORT LAUDERDALE, FL, March 29, 2022 (GLOBE NEWSWIRE) — SFLMaven Corp. (OTC Pink: SFLM), (“SFLMaven” or the “Company”) (www.sflmaven.com), a leading provider of high-end luxury goods, is excited to announce unaudited performance results for the week ended Thursday, March 24, 2022.Total Sales of $283k for seven days ended Mar 24 Mar 24 Thursday Night Auction Sales of more than 258k March 2022 on pace...

REDWOOD CITY, Calif., March 29, 2022 (GLOBE NEWSWIRE) — Soleno Therapeutics, Inc. (Soleno) (NASDAQ: SLNO), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today announced the pricing of an underwritten public offering of 40,000,000 shares of its common stock at a public offering price of $0.25 per share and, for certain investors, in lieu of common stock, pre-funded warrants to purchase 20,000,000 shares of its common stock at a public offering price of $0.24 per pre-funded warrant, which represents the per share public offering price for the common stock less the $0.01 per share exercise price for each pre-funded warrant. Each share of common stock or pre-funded warrant is being sold together with one, immediately exercisable common warrant with a five year term to purchase...

SharpLink’s Data-Driven Customer Acquisition Model Showing Increased Results in All Key Conversion Metrics MINNEAPOLIS, March 29, 2022 (GLOBE NEWSWIRE) — SharpLink Gaming Ltd. (Nasdaq:SBET) (“SharpLink” or the “Company”), a pioneer of targeted, data-driven user engagement and conversion solutions for the emerging U.S. sports betting and iGaming industries, today reported that the Company’s integrated C4 solution resulted in a measurable improvement in the conversion of NASCAR.com fans to sports betting depositors with BetMGM for the first five weeks of the 2022 NASCAR racing season. Currently, SharpLink is featuring a BetMGM bet slip module on NASCAR.com’s home page that incorporates C4 bet recommendation algorithms in states where online sports betting has been legalized. Once a NASCAR fan clicks on the bet slip, a BetMGM promotional...